NCT07312734 Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
| NCT ID | NCT07312734 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chris Goss |
| Condition | Cystic Fibrosis (CF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-03-30 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2026-03-30 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.
Eligibility Criteria
Inclusion Criteria: * ≥ 16 years of age on day of study visit * Documentation of CF Diagnosis * Able to expectorate sputum * Percent predicted FEV1 ≥ 30% Exclusion Criteria: * History of solid organ transplantation * History of active malignancy (or treatment for malignancy) in 12 months prior to the study visit * Pregnant
Contact & Investigator
Gina Hong, MD, MHS
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT07312734 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Cystic Fibrosis (CF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07312734 currently recruiting?
Yes, NCT07312734 is actively recruiting participants. Contact the research team at Nikita.midamba@seattlechildrens.org for enrollment information.
Where is the NCT07312734 trial being conducted?
This trial is being conducted at La Jolla, United States, Minneapolis, United States, St Louis, United States, Omaha, United States and 5 additional locations.
Who is sponsoring the NCT07312734 clinical trial?
NCT07312734 is sponsored by Chris Goss. The principal investigator is Gina Hong, MD, MHS at University of Pennsylvania. The trial plans to enroll 300 participants.